Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
EMERYVILLE, Calif., Nov. 08, 2017 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 15,300 shares of the company’s common stock, at a per share exercise price of $27.00, the closing trading price on November 7, 2017, and restricted stock units to acquire 7,650 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
About Adamas Pharmaceuticals, Inc.
At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our portfolio includes: GOCOVRITM (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified-release lacosamide in Phase 1 clinical development for the treatment of partial onset seizures in patients with epilepsy. For more information, please visit www.adamaspharma.com.
Contact:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
[email protected]
